JP2024505143A - 医薬における使用のための４－クロロ－ｎ－［２－［（４－クロロフェニル）メチル］－３－オキソ－１，２，４－チアジアゾール－５－イル］ベンズアミド - Google Patents

医薬における使用のための４－クロロ－ｎ－［２－［（４－クロロフェニル）メチル］－３－オキソ－１，２，４－チアジアゾール－５－イル］ベンズアミド Download PDF

Info

Publication number
JP2024505143A
JP2024505143A JP2023541948A JP2023541948A JP2024505143A JP 2024505143 A JP2024505143 A JP 2024505143A JP 2023541948 A JP2023541948 A JP 2023541948A JP 2023541948 A JP2023541948 A JP 2023541948A JP 2024505143 A JP2024505143 A JP 2024505143A
Authority
JP
Japan
Prior art keywords
benzamide
chlorophenyl
oxo
methyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505143A5 (https=
Inventor
エドランド，トーマス
ウェストマン，ヤコブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagenon AB
Original Assignee
Betagenon AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon AB filed Critical Betagenon AB
Publication of JP2024505143A publication Critical patent/JP2024505143A/ja
Publication of JP2024505143A5 publication Critical patent/JP2024505143A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023541948A 2021-01-12 2022-01-11 医薬における使用のための４－クロロ－ｎ－［２－［（４－クロロフェニル）メチル］－３－オキソ－１，２，４－チアジアゾール－５－イル］ベンズアミド Pending JP2024505143A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2100352.0 2021-01-12
GBGB2100352.0A GB202100352D0 (en) 2021-01-12 2021-01-12 New methods
PCT/GB2022/050054 WO2022153042A1 (en) 2021-01-12 2022-01-11 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide for use in medicine

Publications (2)

Publication Number Publication Date
JP2024505143A true JP2024505143A (ja) 2024-02-05
JP2024505143A5 JP2024505143A5 (https=) 2025-02-21

Family

ID=74667674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541948A Pending JP2024505143A (ja) 2021-01-12 2022-01-11 医薬における使用のための４－クロロ－ｎ－［２－［（４－クロロフェニル）メチル］－３－オキソ－１，２，４－チアジアゾール－５－イル］ベンズアミド

Country Status (12)

Country Link
US (1) US20240082222A1 (https=)
EP (1) EP4277625A1 (https=)
JP (1) JP2024505143A (https=)
KR (1) KR20230159375A (https=)
CN (1) CN117320716A (https=)
AU (1) AU2022208237A1 (https=)
BR (1) BR112023013828A2 (https=)
CA (1) CA3208099A1 (https=)
GB (1) GB202100352D0 (https=)
IL (1) IL304392A (https=)
MX (1) MX2023008263A (https=)
WO (1) WO2022153042A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11691954B2 (en) 2019-10-18 2023-07-04 Betagenon Ab Formulations
WO2025027205A1 (en) * 2023-08-03 2025-02-06 Betagenon Ab Treatment of cancer with the pdk inhibitor 4-chloro-n-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide
WO2025252672A1 (en) * 2024-06-03 2025-12-11 Betagenon Ab Use of tryptophan and metabolites thereof as biomarkers for treatment methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509914A (ja) * 2004-08-10 2008-04-03 タロー・ファーマシューティカル・インダストリーズ・リミテッド ５，５−ジフェニルバルビツル酸の改良されたバイオアベイラビリティ及び高められた脳送達のための組成物及び方法
JP2012532854A (ja) * 2009-07-08 2012-12-20 バルティック バイオ アーベー 医薬として有用な化合物
JP2013531057A (ja) * 2010-07-21 2013-08-01 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド テトラヒドロイソキノリン誘導体の塩および溶媒和物
JP2016534081A (ja) * 2013-10-25 2016-11-04 アンテシップ バイオベンチャーズ トゥー エルエルシー 治療用のゾレドロン酸または関連化合物の経口投与用組成物
WO2020095010A1 (en) * 2018-11-05 2020-05-14 Balticgruppen Bio Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects
JP2022553268A (ja) * 2019-10-18 2022-12-22 ベタゲノン アーベー 新製剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11691954B2 (en) * 2019-10-18 2023-07-04 Betagenon Ab Formulations

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509914A (ja) * 2004-08-10 2008-04-03 タロー・ファーマシューティカル・インダストリーズ・リミテッド ５，５−ジフェニルバルビツル酸の改良されたバイオアベイラビリティ及び高められた脳送達のための組成物及び方法
JP2012532854A (ja) * 2009-07-08 2012-12-20 バルティック バイオ アーベー 医薬として有用な化合物
JP2013531057A (ja) * 2010-07-21 2013-08-01 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド テトラヒドロイソキノリン誘導体の塩および溶媒和物
JP2016534081A (ja) * 2013-10-25 2016-11-04 アンテシップ バイオベンチャーズ トゥー エルエルシー 治療用のゾレドロン酸または関連化合物の経口投与用組成物
WO2020095010A1 (en) * 2018-11-05 2020-05-14 Balticgruppen Bio Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects
JP2022553268A (ja) * 2019-10-18 2022-12-22 ベタゲノン アーベー 新製剤

Also Published As

Publication number Publication date
AU2022208237A1 (en) 2023-08-10
CA3208099A1 (en) 2022-07-21
EP4277625A1 (en) 2023-11-22
KR20230159375A (ko) 2023-11-21
WO2022153042A1 (en) 2022-07-21
US20240082222A1 (en) 2024-03-14
CN117320716A (zh) 2023-12-29
AU2022208237A9 (en) 2024-07-25
IL304392A (en) 2023-09-01
MX2023008263A (es) 2023-09-12
BR112023013828A2 (pt) 2023-10-03
GB202100352D0 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
KR100501034B1 (ko) 셀레코시브 조성물
EP1617816B1 (en) Nanoparticulate meloxican formulations
JP2024505143A (ja) 医薬における使用のための４－クロロ－ｎ－［２－［（４－クロロフェニル）メチル］－３－オキソ－１，２，４－チアジアゾール－５－イル］ベンズアミド
JP7771316B2 (ja) 組成物
TW201113050A (en) 3-cyanoquinoline tablet formulations and uses thereof
WO2004054574A1 (ja) 経口固形医薬
NZ224497A (en) Pharmaceutical composition comprising flunarizine
US12162850B2 (en) Formulations
CN112584834B (zh) 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物
AU2019354771A1 (en) Combination therapy for the treatment of uveal melanoma
WO2010110428A1 (ja) 掻痒の予防及び／または治療剤
EP4346773B1 (en) A plurality of tasquinimod particles and use thereof
WO2021009505A1 (en) New formulations
KR102511672B1 (ko) 의약 조성물, 그 제조방법 및 사용
KR20260057455A (ko) Pkc 저해제를 포함하는 약제학적 조성물
CN119896660A (zh) 酰胺衍生物在制备治疗或预防皮肤辐射损伤药物上的应用
HK40107035B (en) A plurality of tasquinimod particles and use thereof
HK40107035A (en) A plurality of tasquinimod particles and use thereof
WO2025218795A1 (zh) 一种药物组合物及其应用
CN113350370A (zh) 聚乙二醇在预防和/或治疗肿瘤中的应用
WO2021083347A1 (zh) 喹唑啉衍生物或其盐、或其药物组合物的用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260423